Literature DB >> 23199005

Dosage finding for low-dose spinal anaesthesia using hyperbaric prilocaine in patients undergoing perianal outpatient surgery.

V Gebhardt1, A Herold, C Weiss, A Samakas, M D Schmittner.   

Abstract

BACKGROUND: Hyperbaric prilocaine 20 mg/ml may be preferable for perianal outpatient surgery. The aim of this prospective, single-centre, randomised, single-blinded, controlled clinical trial was to determine the optimal dosage of hyperbaric prilocaine 20 mg/ml for a spinal anaesthesia (SPA) in patients undergoing perianal outpatient surgery.
METHODS: One hundred and twenty patients (18-80 years/American Society of Anesthesiologists grade I-III) were enrolled in this study. The patients were randomised to receive 10, 20 or 30 mg of prilocaine for SPA. We measured expansion of the sensory and motor block, evaluated times to walk, void and being eligible for discharge, and determined the demand of analgesics.
RESULTS: 116/120 patients were available for analysis. The expansion of the sensory block gained with an increasing dosage: 10 mg: 3(1-6) dermatomes; 20 mg: 4(2-6) dermatomes; 30 mg: 5(3-7) dermatomes (P < 0.0001). Dermatomes were counted upwards beginning with S(5). Also, the motor block gained with an increased dosage (Bromage score 1-3: 10 mg: n = 3, 20 mg: n = 8 and 30 mg: n = 18, P = 0.0002). Patients receiving 10 mg were ready for discharge earlier compared with both other groups (10 mg: 199 ± 39 min; 20 mg: 219 ± 47 min; 30 mg: 229 ± 32 min, P = 0.0039). Pain occurred earlier in the 10 mg group than in the 30 mg group (10 mg: 168 ± 36 min; 30 mg: 205 ± 33 min, P = 0.0427). The demand of additional analgesics was comparable in all dosage groups.
CONCLUSION: Hyperbaric prilocaine 20 mg/ml can be applied in dosages of 10, 20 and 30 mg for SPA in perianal surgery. Because of sufficient analgesia, missing motor block and shorter recovery times, 10 mg of hyperbaric prilocaine 20 mg/ml can be recommended for perianal outpatient surgery.
© 2012 The Authors. Acta Anaesthesiologica Scandinavica © 2012 The Acta Anaesthesiologica Scandinavica Foundation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23199005     DOI: 10.1111/aas.12031

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  7 in total

1.  Quantification of systemic o-toluidine after intrathecal administration of hyperbaric prilocaine in humans: a prospective cohort study.

Authors:  Emmanuel Guntz; Andrea Carini; Stephan Koslitz; Thomas Brüning; Panayota Kapessidou; Tobias Weiss
Journal:  Arch Toxicol       Date:  2021-01-21       Impact factor: 5.153

2.  A comparison of 0.375% ropivacaine psoas compartment block and 2% prilocaine spinal anaesthesia in dogs undergoing tibial plateau levelling osteotomy.

Authors:  Diego Sarotti; Elena Lardone; Lisa Piras; Davide Mancusi; Paolo Franci
Journal:  BMC Vet Res       Date:  2022-05-12       Impact factor: 2.792

3.  Retrospective analysis of mepivacaine, prilocaine and chloroprocaine for low-dose spinal anaesthesia in outpatient perianal procedures.

Authors:  Volker Gebhardt; Kevin Kiefer; Dieter Bussen; Christel Weiss; Marc D Schmittner
Journal:  Int J Colorectal Dis       Date:  2018-05-13       Impact factor: 2.571

4.  Spinal anaesthesia with hyperbaric prilocaine in day-case perianal surgery: randomised controlled trial.

Authors:  Ozden Gorgoz Kaban; Dilek Yazicioglu; Taylan Akkaya; M Murat Sayin; Duray Seker; Haluk Gumus
Journal:  ScientificWorldJournal       Date:  2014-10-14

Review 5.  Prilocaine hydrochloride 2% hyperbaric solution for intrathecal injection: a clinical review.

Authors:  Alberto Manassero; Andrea Fanelli
Journal:  Local Reg Anesth       Date:  2017-03-31

Review 6.  Spinal anaesthesia for ambulatory surgery.

Authors:  W Rattenberry; A Hertling; R Erskine
Journal:  BJA Educ       Date:  2019-08-13

7.  Tailored Surgery in Inguinal Hernia Repair. The Role of Subarachnoid Anesthesia: A Retrospective Study.

Authors:  Piergaspare Palumbo; Sofia Usai; Chiara Amatucci; Saverio Cerasari; Bruno Perotti; Luca Ruggeri; Roberto Cirocchi; Guglielmo Tellan
Journal:  Open Med (Wars)       Date:  2019-10-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.